Given the limitations of PD-L1 as a predictive biomarker, it is imperative to further investigate the role of CD274/PD-L1 amplification in MPNST as a potentially significant predictive biomarker in immuno-oncology. This evidence concerns the gene CD274 and malignant peripheral nerve sheath tumor.